Uploaded February 2012 | Updated September 2026, 2 hours ago
Please enjoy a preview of this lecture presented by Enst R. von Schwarz, M.D., Ph.D.at the Clinical Applications for Age Management Medicine Conference in Las Vegas.
Growth hormone (GH) is an anabolic hormone released from the anterior pituitary that regulates somatic growth. Indirectly, and clinically most significant, GH stimulates the production of insulin-like growth factor-I (IGF) in the liver (endocrine action) and in peripheral tissue states of growth hormone (GH) and testosterone deficiency have been detected among a proportion of HF patients, which usually is not addressed. Patients with idiopathic dilated cardiomyopathy (DCM) who present with HF have lower levels of circulating GH and IGF compared to healthy controls. Similar low baseline levels of GH and IGF were found in patients with moderate HF caused by myocardial ischemia. Of interest, others unveiled contradictory results, elevated levels of GH in patients with HF. Because the elevated levels of GH were not all immunologically functional, low levels of IGF existed in these patients lending to the term 'growth hormone resistance'. This phenomenon occurs primarily in HF patients with coexistent cardiac cachexia. Preliminary data on GH therapy in patients with heart failure for symptom improvement is promising, however, further large randomized control trials are warranted before definitive conclusions can be drawn.
Visit our website agemed.org for the latest meeting details including conference schedule, academic agenda, faculty and e-journal archives for the latest industry news.
Or contact us at conference@agemed.org
Please enjoy a preview of this lecture presented by Enst R. von Schwarz, M.D., Ph.D.at the Clinical Applications for Age Management Medicine Conference in Las Vegas.
Growth hormone (GH) is an anabolic hormone released from the anterior pituitary that regulates somatic growth. Indirectly, and clinically most significant, GH stimulates the production of insulin-like growth factor-I (IGF) in the liver (endocrine action) and in peripheral tissue states of growth hormone (GH) and testosterone deficiency have been detected among a proportion of HF patients, which usually is not addressed. Patients with idiopathic dilated cardiomyopathy (DCM) who present with HF have lower levels of circulating GH and IGF compared to healthy controls. Similar low baseline levels of GH and IGF were found in patients with moderate HF caused by myocardial ischemia. Of interest, others unveiled contradictory results, elevated levels of GH in patients with HF. Because the elevated levels of GH were not all immunologically functional, low levels of IGF existed in these patients lending to the term 'growth hormone resistance'. This phenomenon occurs primarily in HF patients with coexistent cardiac cachexia. Preliminary data on GH therapy in patients with heart failure for symptom improvement is promising, however, further large randomized control trials are warranted before definitive conclusions can be drawn.
Visit our website agemed.org for the latest meeting details including conference schedule, academic agenda, faculty and e-journal archives for the latest industry news.
Or contact us at conference@agemed.org
